Cas:61338-18-9 4-oxo-8-(trifluoromethyl)-1H-quinoline-3-carbonitrile manufacturer & supplier

Chemical Name:4-oxo-8-(trifluoromethyl)-1H-quinoline-3-carbonitrile

CAS.NO:61338-18-9

Synonyms:4-oxo-8-(trifluoromethyl)-1H-quinoline-3-carbonitrile

Molecular Formula:C₁₁H₅F₃N₂O

Molecular Weight:238.16500

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:306.7ºC at 760 mmHg

Density:1.48g/cm3

Index of Refraction:1.557

PSA:56.65000

Exact Mass:238.03500

LogP:2.41858

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-oxo-8-(trifluoromethyl)-1H-quinoline-3-carbonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-oxo-8-(trifluoromethyl)-1H-quinoline-3-carbonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-oxo-8-(trifluoromethyl)-1H-quinoline-3-carbonitrile Use and application,4-oxo-8-(trifluoromethyl)-1H-quinoline-3-carbonitrile technical grade,usp/ep/jp grade.

Related News: The API is not made by only one reaction from the raw materials but rather it becomes an API via several chemical compounds. 4-oxo-8-(trifluoromethyl)-1H-quinoline-3-carbonitrile manufacturer Ultimately there’s likely a broad mix of social, cultural and economic drivers at play, suggested Lona Sandon, program director of the Department of Clinical Nutrition in the School of Health Professions at the UT Southwestern Medical Center in Dallas. She was not part of the research. 4-oxo-8-(trifluoromethyl)-1H-quinoline-3-carbonitrile supplier The API is not made by only one reaction from the raw materials but rather it becomes an API via several chemical compounds. 4-oxo-8-(trifluoromethyl)-1H-quinoline-3-carbonitrile vendor Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. 4-oxo-8-(trifluoromethyl)-1H-quinoline-3-carbonitrile factory Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview.